United Therapeutics Announces FDA Approval of Tyvaso DPI™

Published on :

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.

Building Toward a More Sustainable Future – Insights and Tips for Life Science Companies

Published on :

The 2022 ISPE MAST Showcase, hosted at the Turf Valley Resort in Ellicott City, Maryland, held an educational session titled “Sustainability Solution for Tomorrow,” where an esteemed panel of project professionals, corporate real estate directors, and innovators discussed progress, challenges, and potential solutions that life sciences companies can implement to have a lighter ecological footprint.

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

United Therapeutics Logo
Published on :

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation.

Meet Your 2021 BioBuzz Award Winners

Orange banner with photos of people, with text saying "2nd Annual BioBuzz Awards - Presenting Your Winners"
Published on :

Today, we are excited to announce the winners of our 2nd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022

United Therapeutics Logo
Published on :

United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on December 2, 2021, available on Newsweek’s website, recognizes the top 500 most responsible companies in the United States, spanning 14 industries.

2021 BioBuzz Awards Finalists

Published on :

We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch “Braving NeuroBLASToma” in Honor of Childhood Cancer Awareness Month

Published on :

United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player Devon Still and his daughter Leah, a survivor of high-risk neuroblastoma, to launch the educational initiative “Braving NeuroBLASToma” shining a light on the rare cancer affecting immature nerve cells called neuroblasts.iv Neuroblastoma often develops in infants and children under the age of five, but the average age of diagnosis is between one and two years old.

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

Published on :

United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in October 2021. FDA also indicated that they have not identified any potential review issues at this time.

United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA

Published on :

United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 19, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced the submission of a [….]

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Published on :

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease